Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis

Table 6 Responsiveness of ADCT according to change in Patient Global Assessment of Disease (PGAD) and Dermatology Life Quality Index (DLQI)

	Correlation coefficient
Change in ADCT total score vs. change in PGAD	Spearman (95% CI)
Month 1 vs. Baseline, n = 538	0.56*** (0.50, 0.62)
Month 2 vs. Baseline, n = 458	0.58*** (0.51, 0.64)
Month 3 vs. Baseline, n = 372	0.54*** (0.46, 0.61)
Month 6 vs. Baseline, n = 206	0.60*** (0.50, 0.68)
Change in ADCT total score vs. change in DLQI bands	Spearman (95% CI)
Month 1 vs. Baseline, n = 538	0.47*** (0.40, 0.54)
Month 2 vs. Baseline, n = 458	0.48*** (0.41, 0.55)
Month 3 vs. Baseline, n = 372	0.51*** (0.43, 0.58)
Month 6 vs. Baseline, n = 206	0.50*** (0.39, 0.59)
Change in ADCT total score vs. change in DLQI total score	Pearson (95% CI)
Month 1 vs. Baseline, n = 538	0.55*** (0.49, 0.61)
Month 2 vs. Baseline, n = 458	0.57*** (0.50, 0.63)
Month 3 vs. Baseline, n = 372	0.61*** (0.54, 0.67)
Month 6 vs. Baseline, n = 206	0.60*** (0.51, 0.68)

ISSN: 1471-5945